Canada-based startup Avitia, an artificial intelligence (AI)-powered cancer diagnostics company advancing access to fast and affordable molecular testing, has announced its entry into Thailand through a partnership with The Chitrapatima Foundation, a charitable foundation that was established in 1973.
The Foundation, which develops projects to improve the well-being of the Thai people, will establish Thailand’s first advanced liquid biopsy cancer testing ecosystem for hospitals and communities.
Leveraging Avitia’s AI-powered precision diagnostics, Thai people can receive more precise treatment guidance through a simple blood test. The initiative supports the Foundation’s mandate to advance the nation’s health through biomedical innovation, improving the availability of advanced cancer care by removing financial and geographical barriers that have historically limited access.
Furthermore, Thailand’s status as a recognised global healthcare hub means over two billion people across Southeast Asia stand to benefit with improved treatment outcomes from Avitia’s localized testing solution. This builds on Avitia’s global footprint, with over 40,000 patients already tested across Canada, Australia, the United States, and the Middle East.
